Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present invention provides polypeptides comprising or consisting of an amino acid sequence derived from collagen type VI or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant of derivative thereof, wherein the polypeptide, fragment, variant, fusion or derivative is capable of killing or attenuating the growth of microorganisms. Related aspects of the invention provide corresponding isolated nucleic acid molecules, vectors and host cells for making the same. Additionally provided are pharmaceutical compositions comprising a polypeptide of the invention, as well as methods of use of the same in the treatment and/or prevention of microbial infections and in wound care. Also provided are a method of killing microorganisms in vitro and a medical device associated with the pharmaceutical composition.
Core Innovation
The patent discloses collagen type VI-derived polypeptides, including fragments, variants, fusions, and derivatives, that have antimicrobial activity, including killing or attenuating microbial growth. The described polypeptides are positioned as antimicrobial agents against microorganisms such as bacteria and fungi, including Gram-positive and Gram-negative microorganisms, and the document further includes activity against viruses.
The patent describes a mechanism in which antimicrobial activity is linked to heparin-dependent binding to bacterial surfaces via VWA-like regions, followed by membrane binding and membrane disruption/blebbing and exudation. Additional described effects include intracellular content leakage and readouts such as propidium iodide uptake and FITC permeabilization. The document also references anti-endotoxic effects, including LPS-related effects, and associated changes such as nitrite production.
The patent further describes use of the collagen type VI-derived polypeptides in pharmaceutical compositions with pharmaceutically acceptable excipients and in medical applications including treatment and prevention of microbial infections and wound care. It also discloses use against conventional-antibiotic-resistant pathogens. In addition, the document describes medical devices, wound dressings, implants coated or impregnated with the compositions, and kit, medicament, and in vitro sterilising solution applications.
Claims Coverage
The independent claim defines a sequence-selected collagen type VI-derived polypeptide of specific length that has antimicrobial activity.
Collagen type VI γ3(VI)-derived antimicrobial polypeptides
A polypeptide comprising an amino acid sequence selected from SEQ ID NO: 1 from the γ3 chain of collagen type VI, a fragment of SEQ ID NO: 1 comprising at least 20 contiguous amino acids of SEQ ID NO: 1, or a variant of SEQ ID NO: 1 with at least 80% sequence identity to SEQ ID NO: 1, wherein the polypeptide is between 20 and 200 amino acids in length and has antimicrobial activity.
Charged antimicrobial polypeptides
The polypeptide has a charge ranging from +2 to +9.
Hydrophobic-residue antimicrobial polypeptides
The polypeptide has at least 30% hydrophobic residues.
Short-length antimicrobial polypeptides
The polypeptide has a length between 25 and 35 amino acids.
Highly identity-matched variants
The polypeptide is a variant that has at least 90% sequence identity with the amino acid sequence of SEQ ID NO: 1.
Pharmaceutical composition with the antimicrobial polypeptide
A pharmaceutical composition that includes the polypeptide together with a pharmaceutically acceptable excipient, diluent, carrier, buffer, or adjuvant.
Across the independent claim and its refinements, the claimed coverage centers on collagen type VI γ3(VI)-derived polypeptides of defined length that exhibit antimicrobial activity, with dependent features tightening sequence origin, fragment and variant boundaries, and quantitative properties, and adding a pharmaceutical composition embodiment.
Stated Advantages
Killing or attenuating microbial growth.
Treatment and prevention of microbial infections.
Wound care.
Activity against conventional-antibiotic-resistant pathogens.
Anti-endotoxic effects are described, including LPS-related effects.
In vivo invasive infection model benefits are described (mouse survival).
Documented Applications
Treatment and prevention of microbial infections.
Wound care.
Use against conventional-antibiotic-resistant pathogens.
Medical devices, wound dressings, and implants coated or impregnated with the compositions.
Kit and medicament application.
In vitro sterilising solution application.
Interested in licensing this patent?